News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
716,003 Results
Type
Article (42386)
Company Profile (437)
Press Release (673180)
Multimedia
Podcasts (80)
Webinars (13)
Section
Business (208779)
Career Advice (2022)
Deals (36012)
Drug Delivery (104)
Drug Development (83592)
Employer Resources (173)
FDA (16444)
Job Trends (15107)
News (352870)
Policy (33095)
Tag
Academia (2643)
Accelerated approval (6)
Adcomms (24)
Allergies (88)
Alliances (50975)
ALS (101)
Alzheimer's disease (1437)
Antibody-drug conjugate (ADC) (147)
Approvals (16426)
Artificial intelligence (282)
Autoimmune disease (26)
Automation (17)
Bankruptcy (372)
Best Places to Work (11841)
BIOSECURE Act (19)
Biosimilars (107)
Biotechnology (331)
Bladder cancer (84)
Brain cancer (27)
Breast cancer (301)
Cancer (2390)
Cardiovascular disease (192)
Career advice (1690)
Career pathing (30)
CAR-T (163)
Cell therapy (462)
Cervical cancer (20)
Clinical research (67898)
Collaboration (903)
Company closure (2)
Compensation (578)
Complete response letters (24)
COVID-19 (2650)
CRISPR (47)
C-suite (264)
Cystic fibrosis (107)
Data (2376)
Decentralized trials (2)
Denatured (29)
Depression (52)
Diabetes (280)
Diagnostics (6442)
Digital health (20)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (127)
Drug pricing (114)
Drug shortages (26)
Duchenne muscular dystrophy (104)
Earnings (88322)
Editorial (43)
Employer branding (21)
Employer resources (147)
Events (116257)
Executive appointments (765)
FDA (17846)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (811)
Gene editing (119)
Generative AI (21)
Gene therapy (343)
GLP-1 (759)
Government (4521)
Grass and pollen (4)
Guidances (162)
Healthcare (19152)
Huntington's disease (25)
IgA nephropathy (31)
Immunology and inflammation (140)
Indications (30)
Infectious disease (2798)
Inflammatory bowel disease (150)
Inflation Reduction Act (12)
Influenza (53)
Intellectual property (100)
Interviews (312)
IPO (16811)
IRA (43)
Job creations (3704)
Job search strategy (1434)
Kidney cancer (10)
Labor market (43)
Layoffs (507)
Leadership (18)
Legal (7987)
Liver cancer (77)
Lung cancer (333)
Lymphoma (159)
Machine learning (9)
Management (58)
Manufacturing (339)
MASH (80)
Medical device (13536)
Medtech (13541)
Mergers & acquisitions (19773)
Metabolic disorders (744)
Multiple sclerosis (85)
NASH (19)
Neurodegenerative disease (108)
Neuropsychiatric disorders (33)
Neuroscience (2035)
NextGen: Class of 2025 (6755)
Non-profit (4550)
Now hiring (40)
Obesity (394)
Opinion (224)
Ovarian cancer (83)
Pain (96)
Pancreatic cancer (89)
Parkinson's disease (161)
Partnered (22)
Patents (248)
Patient recruitment (117)
Peanut (47)
People (58742)
Pharmaceutical (86)
Pharmacy benefit managers (21)
Phase I (21340)
Phase II (29968)
Phase III (22144)
Pipeline (1410)
Policy (156)
Postmarket research (2601)
Preclinical (9161)
Press Release (67)
Prostate cancer (112)
Psychedelics (37)
Radiopharmaceuticals (264)
Rare diseases (412)
Real estate (6015)
Recruiting (66)
Regulatory (22798)
Reports (48)
Research institute (2417)
Resumes & cover letters (351)
Rett syndrome (6)
RNA editing (5)
RSV (42)
Schizophrenia (80)
Series A (142)
Series B (97)
Service/supplier (11)
Sickle cell disease (58)
Special edition (19)
Spinal muscular atrophy (152)
Sponsored (30)
Startups (3766)
State (2)
Stomach cancer (14)
Supply chain (69)
Tariffs (51)
The Weekly (49)
Vaccines (719)
Venture capitalists (44)
Weight loss (258)
Women's health (38)
Worklife (17)
Date
Today (116)
Last 7 days (986)
Last 30 days (3297)
Last 365 days (33480)
2025 (12285)
2024 (36302)
2023 (41015)
2022 (52276)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (736)
Alabama (59)
Alaska (7)
Arizona (241)
Arkansas (14)
Asia (39311)
Australia (6541)
California (6573)
Canada (2082)
China (555)
Colorado (281)
Connecticut (295)
Delaware (161)
Europe (85996)
Florida (961)
Georgia (217)
Idaho (57)
Illinois (567)
India (25)
Indiana (327)
Iowa (12)
Japan (175)
Kansas (109)
Kentucky (25)
Louisiana (12)
Maine (62)
Maryland (943)
Massachusetts (4974)
Michigan (228)
Minnesota (412)
Mississippi (2)
Missouri (83)
Montana (29)
Nebraska (25)
Nevada (68)
New Hampshire (67)
New Jersey (1837)
New Mexico (30)
New York (1836)
North Carolina (1061)
North Dakota (8)
Northern California (2874)
Ohio (213)
Oklahoma (14)
Oregon (38)
Pennsylvania (1448)
Puerto Rico (13)
Rhode Island (34)
South America (1111)
South Carolina (26)
South Dakota (1)
Southern California (2456)
Tennessee (106)
Texas (971)
United States (24707)
Utah (191)
Virginia (157)
Washington D.C. (66)
Washington State (590)
West Virginia (3)
Wisconsin (57)
716,003 Results for "poseida therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Roche Nears Completion of Poseida Acquisition Worth Up to $1.5B
In a deal expected to close in Q1 2025, Roche will gain access to Poseida’s off-the-shelf CAR T candidates.
January 8, 2025
·
3 min read
·
Tristan Manalac
Press Releases
Roche purchases shares in tender offer for Poseida Therapeutics, Inc.
January 8, 2025
·
5 min read
Press Releases
Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.
November 26, 2024
·
9 min read
Biotech Beach
Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders
Poseida Therapeutics, Inc. announced that its virtual Annual Meeting of Stockholders will be held on Monday, June 17, 2024 at 1:00 p.m. PT.
June 3, 2024
·
2 min read
Press Releases
Poseida Therapeutics to Present at Two Upcoming Investor Conferences
November 12, 2024
·
1 min read
Business
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced updates and financial results for the first quarter ended March 31, 2024.
May 14, 2024
·
14 min read
Business
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
Astellas Pharma Inc. and Poseida Therapeutics, Inc. today announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, “Xyphos”) and Poseida have entered into a research collaboration and license agreement to develop novel convertibleCAR® programs by combining the innovative cell therapy platforms from each of the companies.
May 1, 2024
·
8 min read
Press Releases
Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies
November 26, 2024
·
13 min read
Press Releases
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2024
November 8, 2024
·
17 min read
Press Releases
Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash
December 10, 2024
·
8 min read
1 of 71,601
Next
